What price target do analysts set for fold?
What price target have analysts set for FOLD? 10 brokerages have issued 1 year price objectives for Amicus Therapeutics' shares. Their forecasts range from $12.00 to $17.00. On average, they expect Amicus Therapeutics' share price to reach $15.25 in the next twelve months.
Where can I buy shares of fold?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Where does fold rank among US stocks?
Growth is the dimension where FOLD ranks best; there it ranks ahead of 85.56% of US stocks. The strongest trend for FOLD is in Growth, which has been heading up over the past 146 days.
What is fold's cashflow from operations growth rate?
The 2 year net cashflow from operations growth rate now stands at -30.05%. Over the past 33 months, FOLD's revenue has gone up $202,686,000. The table below shows FOLD's growth in key financial areas (numbers in millions of US dollars).
Is fold stock a good buy?
The consensus among 3 Wall Street analysts covering (NASDAQ: FOLD) stock is to Strong Buy FOLD stock.
Is Amicus Therapeutics a buy?
Amicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Why is fold stock down?
Amicus Therapeutics (FOLD) said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday. The biotech company pitted its drug, known as AT-GAA, against Sanofi (SNY) Genzyme's Lumizyme in patients with Pompe disease.
What does fold mean in stocks?
Related Definitions folding stock means a stock that is designed to be, or capable of being, folded in any way to reduce the length of a firearm. Sample 1.
Is FOLD stock a buy right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currentl...
Will Amicus Therapeutics' stock price go up in 2022?
8 equities research analysts have issued 1-year target prices for Amicus Therapeutics' shares. Their forecasts range from $14.00 to $16.00. On aver...
How has Amicus Therapeutics' stock price performed in 2022?
Amicus Therapeutics' stock was trading at $11.55 at the beginning of the year. Since then, FOLD shares have decreased by 27.1% and is now trading a...
When is Amicus Therapeutics' next earnings date?
Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.30) ea...
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for...
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the following people: Mr. John F. Crowley , Chairman & CEO (Age 55, Pay $2.06M) ( LinkedIn Profile...
What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?
21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com . John F. Crowley has an approval rating of 48% among Amicus Ther...
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regenero...
About Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases.
Signals & Forecast
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Amicus Therapeutics stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are negative selling more shares than they are buying in Amicus Therapeutics
Amicus Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Amicus Therapeutics
In the last 100 trades there were 1.28 million shares bought and 1.96 million shares sold. The last trade was done 37 days ago by Crowley John F who sold 438.22 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Component Grades
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
FOLD POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
FOLD Stock Summary
FOLD scores best on the Growth dimension, with a Growth rank ahead of 80.83% of US stocks.
FOLD Valuation Summary
Of note is the ratio of Amicus Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 19.49% of US stocks have a lower such ratio.
FOLD Growth Metrics
FOLD's price/sales ratio is 10.8; this is 4.85% lower than that of the median Healthcare stock.
FOLD's Quality Factors
The 3 year net income to common stockholders growth rate now stands at -176.78%.
Latest FOLD News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
